pubmed.ncbi.nlm.nih.gov

Annexin A4 is a promising therapeutic target for the treatment of platinum-resistant cancers - PubMed

Review

Annexin A4 is a promising therapeutic target for the treatment of platinum-resistant cancers

Shinya Matsuzaki et al. Expert Opin Ther Targets. 2014 Apr.

Abstract

Introduction: Platinum drugs are widely used for the treatment of testicular, bladder, ovarian, colorectal, lung and prostate cancers. With regard to ovarian cancer in particular, the prognosis is poor for tumours that are (or have become) platinum-resistant. Determining the mechanism underlying platinum resistance may aid in the identification of therapeutic targets for the treatment of platinum-resistant tumours.

Areas covered: This review gives an overview of the characteristics and functions of Annexin (Anx) A4, the mechanism of Anx A4-induced platinum resistance, the association between platinum resistance and platinum transporters, recent reports that Anx A4 overexpression promotes the efflux of platinum drugs via platinum transporters and the association between other Anxs and chemoresistance. The reader will gain an understanding of recent studies on the mechanism of Anx A4-induced chemoresistance. Anx A4 represents a therapeutic target for the treatment of Anx A4-overexpressing platinum-resistant tumours.

Expert opinion: Anx A4 is overexpressed in ovarian clear cell carcinoma (CCC), and enhanced Anx A4 expression induces platinum resistance. Recent studies showed that Anx A4 is also associated with platinum resistance in cancers other than ovarian CCC. Furthermore, other Anxs are reportedly associated with chemoresistance, suggesting a relationship between the Anx family and chemoresistance.

PubMed Disclaimer

Cited by

[Shikonin induces cell death by inhibiting glycolysis in human testicular cancer I-10 and seminoma TCAM-2 cells].
Yao Y, Zhang C, Han B, Tang Y, Xiong Y, Wang S. Yao Y, et al. Nan Fang Yi Ke Da Xue Xue Bao. 2020 Sep 30;40(9):1288-1294. doi: 10.12122/j.issn.1673-4254.2020.09.10. Nan Fang Yi Ke Da Xue Xue Bao. 2020. PMID: 32990238 Free PMC article. Chinese.
Potential targets for ovarian clear cell carcinoma: a review of updates and future perspectives.
Matsuzaki S, Yoshino K, Ueda Y, Matsuzaki S, Kakuda M, Okazawa A, Egawa-Takata T, Kobayashi E, Kimura T. Matsuzaki S, et al. Cancer Cell Int. 2015 Dec 15;15:117. doi: 10.1186/s12935-015-0267-0. eCollection 2015. Cancer Cell Int. 2015. PMID: 26675567 Free PMC article. Review.
Annexin A protein family: Focusing on the occurrence, progression and treatment of cancer.
Zhang H, Zhang Z, Guo T, Chen G, Liu G, Song Q, Li G, Xu F, Dong X, Yang F, Cao C, Zhong D, Li S, Li Y, Wang M, Li B, Yang L. Zhang H, et al. Front Cell Dev Biol. 2023 Mar 3;11:1141331. doi: 10.3389/fcell.2023.1141331. eCollection 2023. Front Cell Dev Biol. 2023. PMID: 36936694 Free PMC article. Review.
Knockdown of Annexin A2 Enhances Radiosensitivity by Increasing G2/M-Phase Arrest, Apoptosis and Activating the p38 MAPK-HSP27 Pathway in Nasopharyngeal Carcinoma.
He H, Lin K, Zou C, Pan J, Fu W, Zhou Y, Lin H, Chen C, Su Y. He H, et al. Front Oncol. 2022 Mar 17;12:769544. doi: 10.3389/fonc.2022.769544. eCollection 2022. Front Oncol. 2022. PMID: 35371986 Free PMC article.
Placenta Previa Complicated with Endometriosis: Contemporary Clinical Management, Molecular Mechanisms, and Future Research Opportunities.
Matsuzaki S, Nagase Y, Ueda Y, Kakuda M, Maeda M, Matsuzaki S, Kamiura S. Matsuzaki S, et al. Biomedicines. 2021 Oct 26;9(11):1536. doi: 10.3390/biomedicines9111536. Biomedicines. 2021. PMID: 34829767 Free PMC article. Review.

Annexin A4 is a promising therapeutic target for the treatment of platinum-resistant cancers - PubMed